General practitioners have started prescribing Mounjaro, a weight loss injection, to patients under strict rules. The medication, also known as tirzepatide, is designed for individuals with obesity or type 2 diabetes who meet specific criteria.
According to new guidelines, GPs can prescribe Mounjaro to patients with a BMI of 30 or higher, or those with a BMI of 27.5 or higher who have at least one weight-related health condition, such as high blood pressure or high cholesterol. Patients must also have tried other weight loss methods without success.
The introduction of Mounjaro comes as the UK struggles with rising obesity rates, with over 60% of adults classified as overweight or obese. The medication works by mimicking natural hormones that regulate blood sugar and appetite, helping patients feel fuller for longer.
However, GPs are required to closely monitor patients taking Mounjaro due to potential side effects, including nausea, vomiting, and pancreatitis. Patients will need regular check-ups and blood tests to ensure safe treatment.
The rollout of Mounjaro is seen as a significant step in tackling the UK’s obesity crisis, but healthcare professionals emphasize that the medication is not a quick fix. Patients will need to make lifestyle changes, including a healthy diet and regular exercise, to achieve sustainable weight loss.
The strict guidelines aim to ensure that Mounjaro is prescribed responsibly and that patients receive comprehensive support throughout their treatment.
